Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn
About

News

Firstlinks newsletter - 13 August

Graham Hand  |  13 Aug 2020Text size  Decrease  Increase  |  
Email to Friend

Morningstar acquired Firstlinks in October 2019. Join 90,000 unique users and receive the Firstlinks weekly editorials and free investment ebooks.

It's easy to oscillate between vaccine optimism and pessimism depending on the most recent authoritative report. Many companies and countries have a vested interest in hyping up their treatments, but even if a convincing vaccine were discovered soon (as Putin and Moscow claim they have done), it would take most of 2021 to complete the required testing and roll it out globally. In the meantime, politicians must make tough decisions to sustain economies and manage outbreaks rather than pretending we are close to business as usual.

This chart from CBA shows the extraordinary extent to which the Australian economy is relying on government support, with benefit payments driving a rapid increase in household income despite poor wage growth.

CBA benefits

Let's check three vaccine opinions, and anyone can draw a line between them, as where the virus goes, so does the economy.

Ian Bremmer writing in Time Magazine, 6 August 2020:

"This liquidity support (along with optimism about a vaccine) has boosted financial markets and may well continue to elevate stocks. But this financial bridge isn’t big enough to span the gap from past to future economic vitality because COVID-19 has created a crisis for the real economy. Both supply and demand have sustained sudden and deep damage. And it will become progressively harder politically to impose second and third lockdowns.

Investing Compass
Listen to Morningstar Australia's Investing Compass podcast
Take a deep dive into investing concepts, with practical explanations to help you invest confidently.
Investing Compass

That’s why the shape of economic recovery will be a kind of ugly 'jagged swoosh', a shape that reflects a years-long stop-start recovery process and a global economy that will inevitably reopen in stages until a vaccine is in place and distributed globally."

Jagged swoosh

Even at the optimistic end, time delays are significant, as McKinsey's wrote on 4 August 2020:

"The world could get seven to nine vaccines over the next two years given historical vaccine success rates and the current pipeline of candidates. The outlook is even more optimistic if the full pipeline of candidates advances toward clinical trials, tripling the likely number of successful vaccines."

We should also ask, when the world masters COVID-19, what next? The World Health Organisation (WHO) gives a daily virus update with lots of interesting news. But on 10 August, WHO included this longer-term warning:

"We are at greater and greater risk around the world and let's face this. We live on a planet in which we're adding a billion people a decade. We are densely packed, we're exploiting pristine environments, we are creating and driving the ecologic pressure that is creating the risks that are driving the risk at the animal/human species barrier.

There are so many people out there working in the ecologic movement who are seeing this each and every day. We are pressuring the biologic system. We live in a biome, we live in a world of biology and we are actively creating the pressures that are driving the breaches of those barriers and we need to do better at managing the risks associated with that."

So this is not just about COVID-19, as there will be COVID-21 and COVID-23 unless we put far more resources into looking after our ecosystem.

This week, focussing on investing and retirement ...

We start with Brendan Coates and Matt Cowgill who question our preoccupation with superannuation for retirement incomes. Having a place to live and the role of the age pension matters more to most people.

With a lot of attention on the potential bubble of the mega-cap tech stocks, it's easy to overlook that many companies are more expensive and have far worse prospects. Jason Ciccolallo finds a heady 100 and US$3 trillion worth of these companies.

As companies rebuild their balance sheet with capital raisings, Tim Canham and Wik Farwerck have identified three factors which are driving their investment decisions in this new normal. Similarly, Kent Williams finds a sector with promising tailwinds, with local software companies delivering solutions for financial efficiency and customer-centric enhancements.

Stephen Mayne has updated his database on retail Share Purchase Plans, and he awards the 'brickbats and bouquets' for the schemes that are equitable and the ones which are downright unfair.

We regularly hear about the 'fear index', the VIX, but what is it? Tony Dillon explains. Is it really worth the attention it receives whenever the market spits the dummy?

Back on retirement incomes, Arthur Naoumidis descibes five ways to use the family home as a source of income, and why it's likely to become a more common solution in future years.

This week's White Paper from BetaShares is their July 2020 ETF review, where despite market runctions, Australian ETFs reached an all-time high of $67 billion. Check where the money is flowing into.

Morningstar has produced a useful calendar of the company reporting season, so you can watch for results affecting your portfolio.

is the editorial director of Morningstar Australia.

© 2021 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. This information is to be used for personal, non-commercial purposes only. No reproduction is permitted without the prior written consent of Morningstar. Any general advice or 'regulated financial advice' under New Zealand law has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892), or its Authorised Representatives, and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. For more information, refer to our Financial Services Guide (AU) and Financial Advice Provider Disclosure Statement (NZ). Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Morningstar’s full research reports are the source of any Morningstar Ratings and are available from Morningstar or your adviser. Past performance does not necessarily indicate a financial product's future performance. To obtain advice tailored to your situation, contact a licensed financial adviser. Some material is copyright and published under licence from ASX Operations Pty Ltd ACN 004 523 782. The article is current as at date of publication.

Email To Friend